This trial is registered with ClinicalTrials.gov, number NCT02213926.



ClinicalTrials.gov
Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity.



ACP-196